Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod with Alteplase and Thrombectomy in Acute Ischemic Stroke
NCT02956200Phase 2Withdrawn
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fingolimod in ischemic stroke (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Salvaged Ischemic Tissue Index at 7 days. Planned start Nov 2016; status: withdrawn.
02
Drugs
fingolimod
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02956200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956200.